Alterations in the C-terminal region of the HIV-1 accessory gene vpr do not confer clinical advantage to subjects receiving nucleoside antiretroviral therapy.
J Infect Dis
; 189(12): 2181-4, 2004 Jun 15.
Article
em En
| MEDLINE
| ID: mdl-15181564
ABSTRACT
The C terminus of the human immunodeficiency virus type 1 (HIV-1) accessory protein vpr acts in viral cell cycle arrest, nuclear localization, and apoptosis. Polymorphisms in this region are described in series of long-term nonprogression cases. We determined vpr sequences of archived baseline specimens from 96 participants in a historical trial of single- versus double-nucleoside reverse-transcriptase inhibitors. These sequences were then analyzed by study-entry and -outcome characteristics such as baseline absolute CD4(+) T cell count, prior treatment, CD4(+) T cell response, and clinical endpoints. Frequency of C-terminal mutations did not correlate to any measures of disease intensity. Changes in that portion of vpr did not attenuate disease.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV-1
/
Produtos do Gene vpr
/
Inibidores da Transcriptase Reversa
/
Mutação
/
Nucleosídeos
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Estados Unidos